Abstract P5-07-05: Deciphering the inferior prognosis of young women with estrogen receptor-positive early-stage breast cancer through full transcriptome analysis: A FLEX database sub-study

Autor: Shubhada Dhage, Mina Gendy, Nina D'Abreo, Ruth Oratz, Sami G. Diab, VK Gadi, Cathy Graham, Midas Kuilman, Shiyu Wang, Patricia Dauer, Andrea Menicucci, William Audeh, Douglas K. Marks

Publikováno v: Cancer Research. 82:P5-07

Introduction: Young women with estrogen receptor (ER)-positive early-stage breast cancer (EBC) frequently present with larger, higher-grade, more aggressive tumors, with lower ER expression than older women. Post-hoc analyses within the MINDACT and T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::55a6141ced99f65d3c349f6c0e6f3658
https://doi.org/10.1158/1538-7445.sabcs21-p5-07-05

Abstract 4090: Creating research quality cancer genomic data from electronic health records

Autor: Rachel Yung, Kari A. Stephens, Meliha Yetisgen, Andrea Burnett-Hartman, Ashwani Tanwar, Guilherme Freire, Atri Sharma, Jingqing Zhang, Vibhor Gupta, Yike Guo, VK Gadi, Larry Kessler

Publikováno v: Cancer Research. 82:4090-4090

Background: Understanding the impact of precision medicine on medical practice, patient care, and clinical outcomes is a priority for advancing cancer care. With the recent dramatic increase in the use of tumor genomic testing (TGT), records within E

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a507165f164d0a77525e7f7d568aa59
https://doi.org/10.1158/1538-7445.am2022-4090

P1-09-09: Fetal Microchimerism and In Situ Breast Cancer

Autor: JK Eun, VK Gadi

Publikováno v: Cancer Research. 71:P1-09

Background: Haploidentical fetal cells acquired and maintained by a woman in her blood and tissues long after pregnancy completion, also known as fetal microchimerism, is inversely associated with invasive breast cancer. Furthermore, in healthy women

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::004c83110f83bd70d2a8bbfd4b9de544
https://doi.org/10.1158/0008-5472.sabcs11-p1-09-09

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Autor: Tarantino P; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy., Tayob N; Harvard Medical School, Boston, MA.; Division of Data Science, Dana-Farber Cancer Institute, Boston, MA., Villacampa G; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Oncology Data Science Vall d'Hebron Institute of Oncology, Barcelona, Spain., Dang C; Memorial Sloan Kettering Cancer Center, New York, NY., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN., Isakoff SJ; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Valero V; MD Anderson Cancer Center, Houston, TX., Faggen M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Mulvey T; Harvard Medical School, Boston, MA.; Massachusetts General Hospital, Boston, MA., Bose R; Washington University School of Medicine, St Louis, MO., Weckstein D; New Hampshire Oncology Hematology, Manchester, NH., Wolff AC; Johns Hopkins Sidney Kimmel Cancer Center, Washington, DC., Reeder-Hayes K; University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC., Rugo HS; University of California, San Francisco, CA., Ramaswamy B; Ohio State University Comprehensive Cancer Center, Columbus, OH., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID., Hart L; Wake Forest Baptist Health, Winston-Salem, NC., Gadi VK; University of Illinois Cancer Center, Chicago, IL., Constantine M; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Cheng K; North Shore-LIJ Cancer Institute, Lake Success, NY., Garrett AM; Northern Light Cancer Care, Brewer, ME., Marcom PK; Duke University School of Medicine, Durham, NC., Albain K; Loyola University Medical Center, Maywood, IL., DeFusco P; Hartford Healthcare Cancer Institute, Hartford, CT., Tung N; Harvard Medical School, Boston, MA.; Beth Israel Deaconess Medical Center, Boston, MA., Ardman B; Lowell General Hospital, Lowell, MA., Nanda R; UChicago Medicine, Chicago, IL., Jankowitz RC; Perelman Center for Advanced Medicine, Philadelphia, PA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN., Pohlmann PR; MD Anderson Cancer Center, Houston, TX.; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL., Liu MC; Natera, Inc, Austin, TX., Ruddy KJ; Mayo Clinic, Rochester, NY., Waks AG; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., DeMeo M; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Burstein HJ; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Partridge AH; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Dell'Orto P; IEO European Institute of Oncology, IRCCS, Milan, Italy., Russo L; IEO European Institute of Oncology, IRCCS, Milan, Italy., Krause E; PathAI, Boston, MA., Newhouse DJ; NanoString Technologies, Inc, Boston, MA., Kurt BB; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA., Mittendorf EA; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA., Schneider B; Indiana University School of Medicine, Indianapolis, IN., Prat A; SOLTI Breast Cancer Research Group, Barcelona, Spain.; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain., Winer EP; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Krop IE; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Yale Cancer Center, New Haven, CT., Tolaney SM; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Nov; Vol. 42 (31), pp. 3652-3665. Date of Electronic Publication: 2024 Jun 27.

Systemic Treatment for Brain Metastasis and Leptomeningeal Disease in Breast Cancer Patients.

Autor: Puri S; Neurooncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA., Chaudhry A; Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA., Bayable A; Department of Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Hospital, Baltimore, MD, USA., Ganesh A; Department of Neurology& Rehabilitation, University of Illinois at Chicago, 912 South Wood Street 174N m/c, Chicago, IL, 60612, USA., Daher A; Department of Neurology& Rehabilitation, University of Illinois at Chicago, 912 South Wood Street 174N m/c, Chicago, IL, 60612, USA.; Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL, USA., Gadi VK; Division of Hematology and Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.; Translational Oncology Program, University of Illinois Cancer Center, Chicago, IL, USA., Maraka S; Department of Neurology& Rehabilitation, University of Illinois at Chicago, 912 South Wood Street 174N m/c, Chicago, IL, 60612, USA. smaraka@uic.edu.

Publikováno v: Current oncology reports [Curr Oncol Rep] 2023 Dec; Vol. 25 (12), pp. 1419-1430. Date of Electronic Publication: 2023 Nov 04.